Abstract:Most episodes of acute heart failure (AHF) are characterized by increasing signs and symptoms of congestion, manifested by edema, pleura effusion and/or ascites. Immediately and repeatedly administered intravenous (IV) loop diuretics currently represent the mainstay of initial therapy aiming to achieve adequate diuresis/natriuresis and euvolemia. Despite these efforts, a significant proportion of patients have residual congestion at discharge, which is associated with a poor prognosis. Therefore, a standardized approach is needed. The door to diuretic time should not exceed 60 min. As a general rule, the starting IV dose is 20–40 mg furosemide equivalents in loop diuretic naïve patients or double the preexisting oral home dose to be administered via IV. Monitoring responses within the following first hours are key issues. (1) After 2 h, spot urinary sodium should be ≥50–70 mmol/L. (2) After 6 h, the urine output should be ≥100–150 mL/hour. If these target measures are not reached, the guidelines currently recommend a doubling of the original dose to a maximum of 400–600 mg furosemide per day and in patients with severely impaired kidney function up to 1000 mg per day. Continuous infusion of loop diuretics offers no benefit over intermittent boluses (DOSE trial). Emerging evidence by recent randomized trials (ADVOR, CLOROTIC) supports the concept of an early combination diuretic therapy, by adding either acetazolamide (500 mg IV once daily) or hydrochlorothiazide. Acetazolamide is particularly useful in the presence of a baseline bicarbonate level of ≥27 mmol/L and remains effective in the presence of preexisting/worsening renal dysfunction but should be used only in the first three days to prevent severe metabolic disturbances. Patients should not leave the hospital when they are still congested and/or before optimized long-term guideline-directed medical therapy has been initiated. Special attention should be paid to AHF patients during the vulnerable post-discharge period, with an early follow-up visit focusing on up-titrate treatments of recommended doses within 2 weeks (STRONG-HF).

Emerging Role of Low-dose Loop Diuretics in the Management of Heart Failure Patients to Maintain Euvolemia

The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century

TRANSFORM-HF Trial: Choice of loop diuretic in acute heart failure does not matter!

Proximal versus distal diuretics in congestive heart failure

Loop Diuretics: An Overview of Its History and Evolution

The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings

The management of acute heart failure and diuretic therapy

Torsemide as a Primary Choice in Edema Associated with Heart Failure

Management of loop diuretic resistance in the intensive care unit

Contemporary Decongestive Strategies in Acute Heart Failure

Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure

Unique Pharmacological Properties and Safety Profiles of Loop Diuretics

The Role of Subcutaneous Furosemide in Heart Failure Management: A Systematic Review

Combination Diuretic Therapy to Counter Renal Sodium Avidity in Acute Heart Failure: Trials and Tribulations

Treatment of Acute Decompensated Chronic Heart Failure: Furosemide vs Furosemide and Metolazone: A Cross-Sectional Comparative Study

Use of Guideline-Recommended Heart Failure Drugs in High-, Middle-, and Low-Income Countries: A Systematic Review and Meta-Analysis

Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?

Decongestion (instead of ultrafiltration?)

Loop Diuretics Unique Mechanism of Action

Decongestion in Acute Heart Failure—Time to Rethink and Standardize Current Clinical Practice?

Diuretic therapy and resistance in congestive heart failure